The Hedonistic Imperative – The End of Suffering – Video by David Pearce and Duarte Baltazar

The Hedonistic Imperative – The End of Suffering – Video by David Pearce and Duarte Baltazar

logo_bgDavid Pearce
Duarte Baltazar


Editor’s Note: The U.S. Transhumanist Party has featured this brief video highlighting the thinking of one of our members, transhumanist philosopher David Pearce, on the abolition of suffering. This video, produced by Duarte Baltazar of Utopian Focus, illustrates one possibility for transhumanist messages reaching larger audiences through concise, powerful films that distill particular transhumanist concepts and aspirations.  

~ Gennady Stolyarov II, Chairman, United States Transhumanist Party, April 15, 2018

Description by Duarte Baltazar of Utopian Focus: Learn more about Utopian Focus at https://utopianfocus.com.

Excerpt from “The Hedonistic Imperative” by David Pearce. Read the full essay at https://www.hedweb.com.

States of sublime well-being are destined to become the genetically pre-programmed norm of mental health. It is predicted that the world’s last unpleasant experience will be a precisely dateable event.

The Hedonistic Imperative outlines how genetic engineering and nanotechnology will abolish suffering in all sentient life.

The abolitionist project is hugely ambitious but technically feasible. It is also instrumentally rational and morally urgent. The metabolic pathways of pain and malaise evolved because they served the fitness of our genes in the ancestral environment. They will be replaced by a different sort of neural architecture – a motivational system based on heritable gradients of bliss.

States of sublime well-being are destined to become the genetically pre-programmed norm of mental health. It is predicted that the world’s last unpleasant experience will be a precisely dateable event.

Two hundred years ago, powerful synthetic pain-killers and surgical anesthetics were unknown. The notion that physical pain could be banished from most people’s lives would have seemed absurd. Today most of us in the technically advanced nations take its routine absence for granted. The prospect that what we describe as psychological pain, too, could ever be banished is equally counter-intuitive. The feasibility of its abolition turns its deliberate retention into an issue of social policy and ethical choice.

Video Editing, Post-Production and Soundtrack by Duarte Baltazar

Utopian Focus: https://facebook.com/utopianfocus

Narration by Elvis Andrumora

Circle of Synths: https://www.circleofsynths.com

The U.S. Transhumanist Party Endorses James D. Schultz for New York State Assembly District 2 

The U.S. Transhumanist Party Endorses James D. Schultz for New York State Assembly District 2 

logo_bg


The U.S. Transhumanist Party is pleased to announce the endorsement of our first candidate during the 2018 election season – James D. Schultz, who is running for New York State Assembly District 2 in the 2018 general election. See the Facebook page for Mr. Schultz’s campaign: James Schultz for State Assembly 2018.

Our electronic vote of the members, which took place on April 3-10, 2018, led to an overwhelming endorsement of Mr. Schultz’s candidacy by 86% of the members who cast their votes.

The vote totals are as follows:

Question: Shall the U.S. Transhumanist Party endorse the candidacy of James D. Schultz for New York State Assembly District 2?

Yes: 49 votes – 86.0%
No: 5 votes – 8.8%
Abstain: 3 votes – 5.3%
Total: 57 votes

Accordingly, Mr. Schultz, an independent candidate, will be able to use “Transhumanist Party” as his political party designation, which is allowed pursuant to New York law. We look forward to collaborating with Mr. Schultz’s campaign and updating our members regarding the progress of his efforts as a candidate.

We hope to be able to endorse other candidates during the 2018 election season as well. The criteria for the U.S. Transhumanist Party being able to consider endorsing a candidate are the following:

– The candidate may run as one of the following:

  • A candidate of the U.S. Transhumanist Party in states where the U.S. Transhumanist Party might obtain ballot access in the future;
  • An independent candidate with “Transhumanist Party” as his or her “political party designation” – which is allowed pursuant to the laws of 26 U.S. jurisdictions;
  • An independent candidate endorsed by the members of the U.S. Transhumanist Party;
  • A candidate for nonpartisan office endorsed by the members of the U.S. Transhumanist Party; or
  • A candidate for any other minor political party which specifically identifies itself as a transhumanist-oriented party in substance.

– The candidate may not run in affiliation with the Democratic, Republican, Libertarian, or Green Parties, or any other minor political party which does not specifically identify itself as a transhumanist-oriented party in substance.

If you would like to be considered as a candidate for endorsement by the U.S. Transhumanist Party, please e-mail Chairman Gennady Stolyarov II with an expression of interest. Describe the office for which you plan to run, your background and qualifications, your platform, how it relates to the U.S. Transhumanist Party Platform, and what motivated your interest in running with the endorsement of the U.S. Transhumanist Party.

The U.S. Transhumanist Party Will Have Its Own Conference Room at RAAD Fest 2018. Will You Visit Us There?

The U.S. Transhumanist Party Will Have Its Own Conference Room at RAAD Fest 2018. Will You Visit Us There?

logo_bg

Gennady Stolyarov II


U.S. Transhumanist Party Chairman Gennady Stolyarov II presents an overview of the Transhumanist Party at RAAD Fest 2017

The U.S. Transhumanist Party is pleased to announce that we will have our own conference room available at RAAD Fest 2018 in San Diego, California, during September 20-23, 2018. During the hours after the main RAAD Fest events, visitors – existing Transhumanist Party members, media representatives, researchers, and members of the general public who are curious about our positions and activities – will be able to visit the room to find out about the U.S. Transhumanist Party’s endeavors and ways in which people of all backgrounds and skill sets would be able to contribute. There will be opportunities for new members to sign up and for both formal and informal conversations. We hope to see as many U.S. Transhumanist Party members as possible at RAAD Fest 2018!

It is possible to register for RAAD Fest 2018 at the website raadfest.com. By entering the code TRANSHUMAN, attendees will be able to save $50 off of the cost of registration.

Attendees of limited financial means – such as students – are encouraged to attend, and our conversation with Jim Strole of the Coalition for Radical Life Extension, the organizer of RAAD Fest, has led us to discover that a special no-meals registration price will be offered. (Cost of meals is ordinarily included in the price of admission.)

Further Information from the RAAD Fest Organizers

– To get the special $50 discount, a person needs to register under GENERAL REGISTRATION; enter your code to get a price of  $497 with Meals.
Student Pricing: There is 1 option on the site: You cannot use a discount code with this option, as it has already been discounted to $397 WITHOUT MEALS.
– Student Registration, NO MEALS: Pricing will be $397.
We will have a light selection of finger foods in the room allocated for Transhumanist Party Members at 11.45 a.m. on Friday & Saturday at no cost.

 

U.S. Transhumanist Party Chairman Gennady Stolyarov II Interviewed by Nikola Danaylov of Singularity.FM

U.S. Transhumanist Party Chairman Gennady Stolyarov II Interviewed by Nikola Danaylov of Singularity.FM

logo_bgGennady Stolyarov II
Nikola Danaylov


On March 31, 2018, Gennady Stolyarov II, Chairman of the U.S. Transhumanist Party, was interviewed by Nikola Danaylov, a.k.a. Socrates, of Singularity.FM. A synopsis, audio download, and embedded video of the interview can be found on Singularity.FM here. You can also watch the YouTube video recording of the interview here.

Apparently this interview, nearly three hours in length, broke the record for the length of Nikola Danaylov’s in-depth, wide-ranging conversations on philosophy, politics, and the future.  The interview covered both some of Mr. Stolyarov’s personal work and ideas, such as the illustrated children’s book Death is Wrong, as well as the efforts and aspirations of the U.S. Transhumanist Party. The conversation also delved into such subjects as the definition of transhumanism, intelligence and morality, the technological Singularity or Singularities, health and fitness, and even cats. Everyone will find something of interest in this wide-ranging discussion.

The U.S. Transhumanist Party would like to thank its Director of Admissions and Public Relations, Dinorah Delfin, for the outreach that enabled this interview to happen.

To help advance the goals of the U.S. Transhumanist Party, as described in Mr. Stolyarov’s comments during the interview, become a member for free, no matter where you reside. Click here to fill out a membership application.

U.S. Transhumanist Party General Discussion Thread for the Second Quarter of 2018

U.S. Transhumanist Party General Discussion Thread for the Second Quarter of 2018

logo_bg


The purpose of this post is to facilitate member comments pertaining to transhumanism and the U.S. Transhumanist Party, which might not specifically fit the subjects of any other post or article on the U.S. Transhumanist Party website. This is the place for members to offer suggestions or converse about any areas of emerging technologies and their political, moral, societal, cultural, and esthetic implications. The general discussion thread is also an ideal location to suggest or propose platform planks that may be considered for future platform voting.

The U.S. Transhumanist Party will endeavor to open one of these general comment threads per quarter. This comment thread pertains to the months of April, May, and June 2018.

Type in your comments below. Please note that, to protect against spambots, the first comment by any individual will be moderated. After passing moderation, a civil commenter should be able to post comments without future moderation – although we cannot guarantee that the technical aspect of this functionality will work as intended 100% of the time.

U.S. Transhumanist Party Vote on the Question of Endorsing Candidate James D. Schultz for the New York State Assembly District 2

U.S. Transhumanist Party Vote on the Question of Endorsing Candidate James D. Schultz for the New York State Assembly District 2

logo_bg


The U.S. Transhumanist Party will hold an electronic vote of the membership for a seven-day period ending on 12:01 a.m. U.S. Pacific Time on Wednesday, April 11, 2018, on the question of whether to endorse James D. Schultz, who will be running for New York State Assembly District 2 in the 2018 general election. Registered U.S. Transhumanist Party members as of 12:01 a.m. U.S. Pacific Time on Wednesday, April 4, 2018, would be able to cast their ballots on this question and will be sent their ballots via e-mail.

See the Facebook page for Mr. Schultz’s campaign: James Schultz for State Assembly 2018.

Mr. Schultz would officially be running as an independent candidate, but New York law allows independent candidates to use a “political party designation” next to their names. If endorsed by the U.S. Transhumanist Party membership (a majority of those casting their ballots, excluding abstentions), Mr. Schultz would be able to use “Transhumanist Party” as his political party designation.

James D. Schultz

Statement by James Schultz: 

The reason I want to run as a Transhumanist is to expand the party brand and knowledge of its existence. I one day want to run a local chapter of the party. I believe this is the best way to expand.

My current stage is fundraising, and I am waiting for the legal opportunity to get ballot signatures.

James Schultz’s 8-Point Platform and Parallels in the U.S. Transhumanist Party Platform

1. Legalization of Marijuana

Parallel in U.S. Transhumanist Party Platform [emphasis added]: 

Section XIV [Adopted by a vote of the members during March 26 – April 1, 2017]: The United States Transhumanist Party supports an end to the costly drug war, which is often an infringement upon the lives and liberties of innocent citizens who do not use drugs but fall victim to militant enforcement of drug prohibitions. The United States Transhumanist Party supports legalization of mild recreational drugs such as marijuana.

2. Removal of Red-Light Cameras

Parallel in U.S. Transhumanist Party Platform: 

[No specific mention of red-light cameras, but the U.S. Transhumanist Party does oppose mass surveillance, and there is the possibility of red-light cameras being overly sensitive in identifying “violations” which may have been immaterial or necessary for safety purposes.]

Section I [Adopted by a vote of the members during January 15-21, 2017]: The United States Transhumanist Party strongly supports individual privacy and liberty over how to apply technology to one’s personal life. The United States Transhumanist Party holds that each individual should remain completely sovereign in the choice to disclose or not disclose personal activities, preferences, and beliefs within the public sphere. As such, the United States Transhumanist Party opposes all forms of mass surveillance and any intrusion by governmental or private institutions upon non-coercive activities that an individual has chosen to retain within his, her, or its private sphere. However, the United States Transhumanist Party also recognizes that no individuals should be protected from peaceful criticism of any matters that those individuals have chosen to disclose within the sphere of public knowledge and discourse.

3. Government Funding of Student Laptops and Class Smart Boards

Parallel in U.S. Transhumanist Party Platform: 

Section XII [Adopted by a vote of the members during March 26 – April 1, 2017]: The United States Transhumanist Party holds that present and future societies should provide education systems accessible and available to all in pursuit of factual knowledge to increase intellectual acuity; promote critical thinking and logic; foster creativity; form an enlightened collective; attain health; secure the bounty of liberty for all sentient entities for our posterity; and forge new ideas, meanings, and values.

The United States Transhumanist Party supports efforts to reduce the cost of education while improving its access. In particular, the United States Transhumanist Party supports freely available, open-source, methods of learning, teaching, credentialing, and cultural creation that integrate emerging technologies into every facet of the learning process. The United States Transhumanist Party primarily advocates private innovation to deliver such educational improvements, but also advocates the application of these improvements to all publicly funded educational institutions. The United States Transhumanist Party holds that every person should aspire toward intellectual, moral, and esthetic enlightenment and sophistication and should contribute toward bringing about a new Age of Reason, where the highest reaches of intellectual activity are attainable and eagerly pursued by the majority of the population.

The United States has upheld basic education since the American Revolution. The United States Transhumanist Party believes, in keeping with what basic education was in the 1700s, relative to the state of technology given the advancement in society at the time, that ‘basic’ education should be defined as college, and that a key part of our agenda is to help encourage a more successful generation by paying for a ‘basic’ education up to and including college degrees.

4. Term Limits

[No specific mention in U.S. Transhumanist Party Platform.]

5. Environmental Protection

Parallels in U.S. Transhumanist Party Platform: 

[No generalized mention of environmental protection in U.S. Transhumanist Party Platform, but there is mention of supporting alternative energy sources and protecting particular species of animals from killing and cruelty, as well as support of the environmentally friendly development of biologically identical meat products that do not involve the killing of animals.]

Section XXIV [Adopted by a vote of the members during March 26 – April 1, 2017]: The United States Transhumanist Party supports the promotion of animal welfare to the extent it does not conflict with human well-being. However, the United States Transhumanist Party opposes “animal liberation” movements that seek to return animals to the wilderness or espouse any attempts to separate domesticated animals from human influence. In particular, the United States Transhumanist Party supports the prohibition of cruelty to animals and a complete abolition of euthanasia of healthy animals by animal shelters. The United States Transhumanist Party supports a complete prohibition on the killing of non-contagious, non-aggressive dogs, cats, dolphins, whales, elephants, horses, tortoises, parrots, and primates. Furthermore, the United States Transhumanist Party supports the development and widespread consumption of artificially grown, biologically identical meat products that do not involve the killing of animals.

Section XXXVIII [Adopted by a vote of the members during May 7-13, 2017]The United States Transhumanist Party supports emerging alternative energy sources and their technological implementations. However, the United States Transhumanist Party opposes government subsidies for any energy source – including fossil fuels. Instead, the United States Transhumanist Party holds that superior, cleaner, and more efficient energy sources will also tend to become less costly and more broadly adopted under a system of unfettered market competition and innovation.

6. State Net Neutrality

Parallels in Positions Expressed by the U.S. Transhumanist Party:

Article XV of the U.S. Transhumanist Bill of Rights states,

“All sentient entities, with the exception only of those in legal detention, have the right to private internet access without such access being prohibited or circumvented by either private corporations or governmental bureaucracy.”

Read the statement by Martin van der Kroon, “The U.S. Transhumanist Party Supports Net Neutrality. Do You?

7. Mandatory Police Body Cameras

Parallel in U.S. Transhumanist Party Platform: 

Section XXXIV [Adopted by a vote of the members during May 7-13, 2017]:  The United States Transhumanist Party holds that sousveillance laws should be enacted to ensure that all members of peaceful communities feel safe, to achieve governmental transparency, and to provide counter-balances to any surveillance state. For instance, law-enforcement officials, when interacting with the public, should be required to wear body cameras or similar devices continuously monitoring their activities.

The United States Transhumanist Party supports the use of technologies which increase monitoring of police action and policing activities, with expressed goals of increasing policing accountability.

The United States Transhumanist Party advocates for a requirement that data pertaining to recordings of police action be transmitted and recorded beyond police control, so as to be protected from falsification, deletion, and selective curation by police.

8. Reduced Ballot-Access Requirements

Parallel in U.S. Transhumanist Party Platform: 

Section XIX [Adopted by a vote of the members during March 26 – April 1, 2017]: The United States Transhumanist Party supports an end to the two-party political system in the United States and a substantially greater inclusion of “third parties” in the political process through mechanisms such as proportional representation and the elimination of stringent ballot-access requirements. The United States Transhumanist Party also seeks to limit the influence of lobbying by politically connected special interests, while increasing the influence of advocacy by intelligent laypersons.

The Rise of Oisin Biotechnologies – Interview with Gary Hudson, CEO of Oisin Biotechnologies, by Ariel VA Feinerman

The Rise of Oisin Biotechnologies – Interview with Gary Hudson, CEO of Oisin Biotechnologies, by Ariel VA Feinerman

Ariel VA Feinerman
Gary Hudson


Gary Hudson

Preface

What is ageing? We can define ageing as a process of accumulation of the damage which is just a side-effect of normal metabolism. While researchers still poorly understand how metabolic processes cause damage accumulation, and how accumulated damage cause pathology, the damage itself — the structural difference between old tissue and young tissue — is categorized and understood pretty well. By repairing damage and restoring the previous undamaged — young — state of an organism, we can really rejuvenate it! Sounds very promising, and so it is. And for some types of damage (for example, for senescent cells) it is already proved to work!

Today in our virtual studio somewhere between cold rainy Saint-Petersburg and warm rainy Seattle, we meet Gary Hudson!

He has been involved in private space flight development for over 40 years. Hudson is best known as the founder of Rotary Rocket Company, which in spending ~$30 Million attempted to build a unique single stage to orbit launch vehicle known as the Roton. He helped found Transformational Space T/Space in 2004 and AirLaunch LLC which was awarded the DARPA/USAF FALCON project in 2003.

Previous projects included designs of the Phoenix SSTO, the Percheron, and other rockets, founder of Pacific American Launch Systems, and various consulting projects. Currently, he is the President and CEO of the Space Studies Institute.

Now Hudson brings his excellent engineering skills into rejuvenation biotechnology! He is a founding partner of Oisin Biotechnologies, who are developing a liposomally delivered DNA therapy for the removal of senescent cells from the body. Hudson provided an initial seed donation to help fund the creation of the Methuselah Foundation and SENS Research Foundation.

Interview

Feinerman: Hello, Mr Gary Hudson!

Hudson: Thanks for inviting us to this interview!

Feinerman: You have recently visited an amazing Undoing Aging 2018 conference, which took place in Berlin, 15–17 March, where your colleague, Matthew Scholz, was a speaker. What is your impression?

Hudson: It was a great conference with several important presentations. It put me in mind of the early SENS conferences in Cambridge, UK, which I helped to sponsor. I understand it will now become an annual event. Our CSO Dr. John Lewis also gave an important summary of our work to date.

Feinerman: Will Oisin’s presentations from conference be available for general public?

Hudson: I believe that the SENS Foundation will be posting them but I don’t have details about the timing.

FeinermanYour last interview was in July 2017, more than half a year ago. What has been accomplished?

Hudson: We have conducted many pre-clinical mouse experiments on both cancer and senescent cell removal. All have been successful and produce very remarkable results. We’ve also conducted a pilot toxicity and safety trial on non-human primates. The results of that trial were also successful and encourage us to proceed to human safety trials as soon as regulatory authorities approve them. We have also spun-out a cancer-focused company, Oisin Oncology, and raised a seed round for that venture.

Feinerman: Great to hear! However, when can we see some papers? People usually trust papers more than mere interviews or press releases. Of course, papers need many efforts not related to research but they will allow you attract more attention from general public, researchers, and investors.

Hudson: Papers are being prepared now for submission to major journals, but that process takes time, especially the peer review. For the moment, most of our data is only available to investors and partners in pharma and the biotech industry.

Feinerman: You planned human clinical trials, have you carried them out?

Hudson: It takes quite some time to organize a human trial and to get it approved. Before one can be conducted, we have to set up so-called “GMP (Good Manufacturing Practice) manufacture of our therapeutic, and then we have to conduct “GLP (Good Laboratory Practice) Tox” studies in two different species. Once that is all completed later this year, then we can begin a human safety trial, or a “Phase 1” trial. All this takes time, but we hope that first safety trials in oncology indications might begin this year, or in early 2019.

Feinerman: Does that mean we have a race between Unity Biotechnology and Oisin and you have all chances to win the race?

Hudson: I don’t see it as a race or a competition. I believe that future anti-aging treatment will require multiple complimentary approaches.

Feinerman: When we can expect your therapy available in the clinic?

Hudson: It’s very difficult to predict. I believe that our cancer treatment will make it to the clinic first, and that could happen in less than five years. Since the FDA doesn’t regard ageing as an indication, it may take longer for our SENSOlytic™ treatment to reach the public, since the regulatory environment will need to change.

Feinerman: As Michael Rae has said, we need not to wait when ageing will be recognised as a disease. You can mark your senolytics as a therapy for specific ageing pathology like fibrosis or chronic inflammation in the same way as Unity does.

Hudson: This is certainly true and is part of our strategy, but many of those endpoints are more difficult to ascertain than oncology endpoints. Additionally, going after oncology approvals can be faster and easier to get to clinic. But we will push forward on several fronts as funding permits.

Feinerman: In your previous interview you have said that you make some tweaks to both the promoter side and the effector side of the constructs that will provide even more interesting and useful extensions to the basic capability, but you can’t discuss those for IP reasons. Can you now say about them?

Hudson: I still can’t say too much about them, but we have conducted animal trials on some of these “tweaks” and they work quite well. The downside to the matter is that every “tweak” requires new trials, and our goal is to get something to the clinic as soon as possible, so many of the improvements will have to wait. Progress is limited based on available funds and personnel resources, of course, but we will move as quickly as we can.

Feinerman: Do you use any CAD software to design your constructs? Are you going to make them public so independent engineers will be able to help you identify new useful pairs of promoters and effectors? Your technology is so powerful that Open Source approach would be very helpful!

Hudson: No, the design of the current constructs are very straightforward and simple. As our patents are issued, their design will become public. If people wish to design their own constructs for particular applications they may contact us for collaboration, though we do have several collaborations active at the moment so we may already be working on similar ideas.

Feinerman: What do you think on targeting your machinery on cells with abnormal telomerase activity to kill cancer? Can you use several conditions — like in programming — several promoters to be more specific?

Hudson: If we targeted telomerase we’d also kill stem cells, just like the side effects of much of conventional chemotherapy. That’s probably not a good idea. But multiple promoters, or synthetic promoters, might be used to achieve the aims of killing only cancer cells. Our initial therapeutic will likely just employ p53 promoter targeting, since we have good data that works.

Feinerman: Yeah, the same issue as when we remove or break telomerase gene: there would be nice to do this only in compromised tissue, but as researchers say it is very difficult to make the removal selective. However, it is not a problem with ALT genes, which cause 15–20% of cancers. Are you going to collaborate with the OncoSENS lab? Also killing cells actively expressing telomerase will be very useful in WILT implementation.

Hudson: We’ve had conversations with the SENS Foundation about OncoSENS and cooperated in a preliminary fashion, but I don’t believe it is currently a research priority for them. We already have enough projects to keep us busy for some time, too!

Feinerman: Now you use only suicide gene as an effector, do you plan to use other genes? For example to enhance the cells, give them ability to produce new enzymes, or temporarily shut down telomerase to help anti-cancer therapy to be more effective.

Hudson: We believe we can express any gene under the control of any promoter we wish to use, so the possibilities are almost endless.

Feinerman: Now we know that epigenetic changes (shift) play a huge role in ageing. Even though there is no consensus among researchers whether they are a cause or a consequence of ageing, experiments show that temporal expression of OSKM transcription factors may have some health benefits by restoring “young” epigenetic profiles. You can remember the Belmonte work, for example. However, the problem in their work is that they used transgenic mice and express OSKM in every their cell. If you temporarily express OSKM in an “old” cell, that is OK, you can “rejuvenate” such a cell. While if you express OSKM in a stem cell which is already biologically “young”, you can force the cell into iPSC, which is a way to cancer. Using your machinery we can target only cells which have “old” expression profiles, and involving normal mice! Such a work will be much “cleaner” and safer than Belmonte’s work.

Hudson: With respect to your comments about reprogramming, Oisin is currently working with a university group on exactly this approach, but I can’t say more at this time. We also believe that first you have to clear existing senescent cells, then you can reprogram successfully.

Feinerman: How many resources, finances, and personnel do you need to move as quickly as possible? Do you have open positions? Maybe, some of our readers have enough finances or experience.

Hudson: We could effectively spend tens of millions or dollar or more, very easily, but it isn’t realistic to assume we could raise that amount — and if we did, we’d lose control of Oisin’s ageing focus, since investors would most likely want us to aim at quick returns. We are always interested in talking with “mission minded” investors, however. As for hiring, we have to do that slowly and judiciously, since labour is one of the biggest costs to a start-up company, and over-hiring can sink a project quickly. We already have more potential hires than we can bring on-board.

Feinerman: Now cryptocurrencies and blockchain technologies allow completely new and efficient ways for investments. We can see this as various no-name companies easily rise tens of millions dollars via ICOs for clearly doubtful projects. Would you like to make an ICO? Oisin shows real progress and can easily rise big sums! People say that they will be glad to buy your tokens if you issue them. You have said that you prefer to work with “mission minded” investors. There are thousands people out there who can invest from $1,000 to $100,000 in cryptocurrencies and who believe that radical extension of healthy life is possible!

If you are worried about legal issues, you can use various cryptocurrency investment funds who act like proxies between holders of cryptocurrencies and companies.

Hudson: We have investigated several of these financing options, but we are not expert in this area, so we have been reluctant to move too quickly. But we continue to have conversations with relevant parties. There is a lot of regulatory uncertainty surrounding ICOs, however, so we must move cautiously.

Feinerman: Now we know enough about ageing to defeat our main enemy. Do you agree that first comprehensive rejuvenation panel is not a scientific problem and even not an engineering problem, but a problem of engineering management?

Hudson: I wouldn’t say that there is no science left to do, but as an engineer myself I naturally agree that proper engineering management and program management skills must be brought to bear on the problem of ageing.

Feinerman: One person has said, we get what we ask for. Can we now aim high and publicly claim that our main goal is not additional five years of life but LEV — Longevity Escape Velocity and finally unlimited healthy life?

Hudson: This is a difficult “public relations” problem. Most investors, the scientific community, and the public are not yet ready to embrace the notion of longevity escape velocity. Thus at Oisin we do pitch health span as a primary goal. But personally I don’t believe that you can obtain health span improvements without making significant progress towards LEV. So in the end, I think we get LEV by targeting health span, and we reduce the controversy by doing so.

Feinerman: Some people ask me how to buy your stocks or invest in Oisin. What can you say?

Hudson: We do have a number of private investors (angel investors) who are “mission minded” or “mission focused” and we welcome discussions with qualified investors and firms who share our vision for dealing with ageing and cancer. Accredited investor candidates may contact us at info@oisinbio.com

Feinerman: David Gobel claims that “By advancing tissue engineering and regenerative medicine, we want to create a world where 90-year olds can be as healthy as 50-year olds by 2030.” And I secretly hope that 40 will become new 30 or even 20 by 2030! Can we achieve that — in principle?

Hudson: I certainly hope so! In 2030 I’ll be 80, so I’m looking forward to feeling like I’m 40…

Feinerman: Thank you very much for your amazing answers! That was a real pleasure to talk with such a great man like you. I hope we all will succeed in our goal and will have hundreds, thousands, and — who knows? — maybe even millions years of healthy life!

Hudson: It is kind of you to say so, but I only consider myself fortunate to be working with the really great men and women in the anti-aging community who are doing the real work. I’m only trying to facilitate their efforts and get treatments to the clinic as fast as possible. I don’t know what will be possible in the long term, but anything will be better than letting nature run its course, producing sickness and declining functional health.

Ariel VA Feinerman is a researcher, author, and photographer, who believes that people should not die from diseases and ageing, and whose main goal is to improve human health and achieve immortality.

Message from Ariel VA Feinerman: If you like my work, any help will be appreciated!

PayPal: arielfeinerman@gmail.com

Bitcoin: 1Gz5ebAyPmM9vNAAgpmeX7G3rtKMyWEjb1

Ether: 0x4752d8a8615Cdf48E220f9dbb48654C7791716ee

Bitcoin Cash: qzh427szlnfyk2k6v547gkpjvafnmzgk35hzagzs82

Proposal for Chimeric Gene Therapy (v1.3.1) – Curing Trauma, Addiction, and Conditioning – Paper by Kyrtin Atreides

Proposal for Chimeric Gene Therapy (v1.3.1) – Curing Trauma, Addiction, and Conditioning – Paper by Kyrtin Atreides

Kyrtin Atreides


Editor’s Note: The U.S. Transhumanist Party has published this research paper and proposal for a practical gene therapy by member Kyrtin Atreides in order to solicit input from other researchers in the field of gene therapy as well as to provide some ideas for further directions in research and practical applications of genetic engineering. The U.S. Transhumanist Party does not itself conduct research or recommend particular medical procedures, so the publication of this paper should be seen as promoting the exploration of research paths that could one day (hopefully sooner rather than later) materialize into viable treatments for curing diseases and lengthening lifespans. 

~ Gennady Stolyarov II, Chairman, United States Transhumanist Party, April 1, 2018

Introduction:

A wise medical director once told me that 50% of those who go into the field of Psychology need psychological help themselves. I suspect that one day I’ll be able to say the same of genetic engineering.

Epigenetics control our neurochemistry, which dictates base level reactions to stimuli, and everything from a bad meal, job, relationship, or traumatic childhood event, to warzone PTSD, can trigger epigenetic changes. [1] De Bellis, M. D., & A.B., A. Z. (2014), [2] Gudsnuk, K., & Champagne, F. A. (2012), [3] Hardy, T. M., & Tollefsbol, T. O. (2011)

Over time these changes build up, and since human society is often highly unstable due to rapid and lopsided progression, the net result is cumulative damage, similar to aging, because epigenetics attempt to attune you to an environment that doesn’t change in compatible ways. [4] Bowers, E. C., & McCullough, S. D. (2017)

What this means is that in order to roll back the clock the epigenetic equation needs to be recalculated in a local space, a process which occurs with a viral knockout, or insertion of new genetic data, within a region surrounding any given gene. The basic idea is that if you alter the dimensions of the space that the epigenetic equation covers via methylation, you cause it to recalculate the ideal distribution and genetic activation for that region based on current data, rather than the trauma which previously altered it.

By causing this update to take place, the gene expression is recalculated to values which are more closely aligned with current needs and environmental factors. Previously in human history, lives were shorter and epigenetic influences served a healthy role in promoting survival, but the problem with amassing a large pile of trauma-induced epigenetic changes becomes acutely apparent as age increases.  [5] Teschendorff, A. E., West, J., & Beck, S. (2013)

Each change is based on data fixed to the point of trauma, and any alteration to that expression is glacially slow, if it occurs at all. Often times such changes break an element of neurochemistry in the sense that the change can’t naturally reverse itself once it has been made, but it can be easily reversed with minor engineering.

Different genes act like functions in code, separate blocks which can function together, but which also contain sites where new code can be placed without causing harm to the current code. In the same way the human genome also contains 8% integrated viral DNA, which makes for an ideal target for gene knock-out.  [6] (International Human Genome Sequencing Consortium, 2001; Smit, 1999)

Proposal Part 1:

What I propose is two-fold. The first step is the creation of a gene therapy which is practically viable, costing no more than $5 per person in production. The second step is testing the top gene sites active in controlling neurochemistry with both knock-out of viral DNA, and knock-in of dormant placeholder DNA, to cause recalculation to take place.

The first is easily accomplished by understanding the nature of why anything evolves in the first place, for survival. If you create a gene therapy whose survival is guaranteed it loses reason to adapt maliciously, because there is no advantage to be gained. A classic case that demonstrates a virus becoming less lethal over time is HIV, where initially it was a death sentence, but over time not only were treatments developed, the virus became less lethal, because that lethality was acting as a detriment to the purpose of survival, and it evolved in order to live longer. [7] Payne, R., Muenchhoff, M., Mann, J., Roberts, H. E., Matthews, P., Adland, E., … Goulder, P. J. R. (2014)

The myriad of bacteria, archaea, viruses, and eukaryotic microbes in our bodies that outnumber our own cells have come to a balanced state, where our bodies are the ecosystem, and as that 8% viral DNA demonstrates a virus is no different, it favors survival and a stable environment. [8] Eloe-Fadrosh, E. A., & Rasko, D. A. (2013)

I mention this because of a key factor which makes gene therapy completely impractical today, 293T cells. Having to use specialty cells for cloning a virus that isn’t replication-competent, and is often very fragile to begin with, is one monumental waste, which is built on the unfounded fear that a replication-competent virus is in and of itself a threat. As machine learning is applied to the human genome, as well as non-human genomes, the error in that line of reasoning will become increasingly apparent.

What we need is a new gene therapy, engineered for high conversion rates, such as Adeno-Associated-Virus-7 or Lentivirus, and hybridized with a more durable, low-symptom (“clinically silent”), low-transmission-potential virus, such as Epstein-Barr Virus. By making such a virus replication-competent, but also self-inactivating (EBV) and able to integrate itself as a genetic landing site capable of being periodically updated, not only is the problem of practicality and cost solved, but the speed with which new research can be tested is greatly accelerated, and the virus is rendered stable. EBV in particular is already present in roughly 95% of adults, as it has integrated with their genomes. When combined with revised best practices any risk of bad-actor genetic engineering remains a practical impossibility.

By keeping the intermediate stages of the gene therapy in a controlled environment and only releasing the end result beyond that point, the Bio-Safety risk remains functionally unchanged, as the hypothetical “bad actor” would still require the same advanced tools, knowledge, and materials to generate a harmful virus as they already do today. The key difference in Bio-Safety terms is that by allowing the field to advance, the benefits and possible means of defense against that hypothetical would move forward, while undermining the root cause of said hypotheticals. This would be roughly equivalent to creating bulletproof sleepwear before the invention of the firearm.

The end result of utilizing such a gene therapy would be a symbiotic relationship with a genetic update mechanism, where increases to lifespan and survival rates favor both parties, resulting in potential rare mutations that better serve that purpose, like a bird evolving a better beak for catching fish.

Selection of EBV to hybridize with Lentivirus would also allow for the therapy to enter dormant cycles, avoiding immune-system rejection, and reactivating when introduced to engineered updates from additional gene therapy treatments. [9] Houldcroft, C. J., & Kellam, P. (2015)

The replication-competent gene therapy can be created with either AAV-7 or Lentivirus by means of recombination during the manufacturing process. An AAV-2 or AAV-7 variant may be preferable, if not required, for the treatment of HIV-positive humans due to the risk of interaction between any Lentivirus gene therapy and the HIV virus. It is however probable that a Lentivirus/EBV chimeric gene therapy would overwrite wild HIV virus variants rather than being overwritten by them, but rigorous testing is required, which development of this therapy would also make possible. This is partly due to the far greater size, complexity, and long-term stability of EBV compared to Lentivirus. [10] Haifeng Chen. (2015)

On a side note the genetics study that led me to realize this epigenetic mechanic was in play is shown here:

[11] Welle, S., Cardillo, A., Zanche, M., & Tawil, R. (2009)

It was by examining the difference between an adult with gene knock-out applied after maturation versus one born with the modification that the mechanic of Methylation Dimensions / Dimensions of DNA was illuminated. Since this process occurs naturally as a part of viral integration, a mechanic had to evolve that could handle the recalculation. The above study also highlights that gene therapies shouldn’t be administered to individuals prior to adulthood, due to the differences in how they impact an individual prior to biological maturation, unless the need is dire, or unless the difference can be corrected upon maturation.

Another failing point of gene therapies as they exist today is that, due to the lack of replication-competence, viral titers act as a choke-point, where the virus is injected in-mass rather than gradually converting cells, massively increasing the risk of cellular toxicity and immunotoxicity. If a gene therapy was replication-competent, even an extremely low dose could achieve a high level of cellular conversion over a period of time, potentially closing in on Bayes Error, regardless of host mass. In effect, the same dose that yields positive results in a mouse could also work for a human. [12] White, M., Whittaker, R., Gándara, C., & Stoll, E. A. (2017)

Proposal Part 2:

Once the new gene therapy is complete, the ability to repair damage at the epigenetic level becomes practical, speeding up the testing process by an order of magnitude, as well as greatly reducing cost.  For the purpose of initial testing and separation of documented effects, knock-out of viral DNA and placeholder-gene knock-in will be targeted to recalculate small regions surrounding key neurochemistry controlling genes, a few of which I’ve listed below:

HTR6 – Chromosome 1 – (5-Hydroxytryptamine Receptor 6) is a Protein Coding gene.  Diseases associated with HTR6 include Acute Stress Disorder and Amnestic Disorder.

NR4A2 – Chromosome 2 – (Nuclear Receptor Subfamily 4 Group A Member 2) is a Protein Coding gene. Diseases associated with NR4A2 include Arthritis and Late-Onset Parkinson Disease. Among its related pathways are Dopaminergic Neurogenesis and Corticotropin-releasing hormone signaling pathway. GO annotations related to this gene include transcription factor activity, sequence-specific DNA binding, and protein heterodimerization activity. An important paralog of this gene is NR4A3.

HES1 – Chromosome 3 – (Hes Family BHLH Transcription Factor 1) is a Protein Coding gene. Among its related pathways are Signaling by NOTCH1 and NOTCH2 Activation and Transmission of Signal to the Nucleus. GO annotations related to this gene include transcription factor activity, sequence-specific DNA binding, and sequence-specific DNA binding. An important paralog of this gene is HES4. [13] Epigen Global Research Consortium(2015)

DRD5 – Chromosome 4 – (Dopamine Receptor D5) is a Protein Coding gene.  This receptor is expressed in neurons in the limbic regions of the brain. It has a 10-fold higher affinity for dopamine than the D1 subtype.

SLC6A3 – Chromosome 5 – (Solute Carrier Family 6 Member 3) is a Protein Coding gene. Diseases associated with SLC6A3 include Parkinsonism-Dystonia, Infantile and Nicotine Dependence, Protection Against.

DRD1 – Chromosome 5 – (Dopamine Receptor D1) is a Protein Coding gene.  Diseases associated with DRD1 include Cerebral Meningioma and Drug Addiction.

TAAR1 – Chromosome 6 – (Trace Amine Associated Receptor 1) is a Protein Coding gene. Although some trace amines have clearly defined roles as neurotransmitters in invertebrates, the extent to which they function as true neurotransmitters in vertebrates has remained speculative. Trace amines are likely to be involved in a variety of physiological functions that have yet to be fully understood.

DDC – Chromosome 7 – (Dopa Decarboxylase) is a Protein Coding gene. Among its related pathways are Dopamine metabolism and Metabolism.

CRH – Chromosome 8 – CRH (Corticotropin Releasing Hormone, aka CRF) is a Protein Coding gene. Diseases associated with CRH include Crh-Related Related Nocturnal Frontal Lobe Epilepsy, Autosomal Dominant and Autosomal Dominant Nocturnal Frontal Lobe Epilepsy. Among its related pathways are G alpha (s) signalling events and Signaling by GPCR. GO annotations related to this gene include receptor binding and neuropeptide hormone activity. [14] Sandman CA, Curran MM, Davis EP, Glynn LM, Head K, Baram TZ.(2018)

HTR7 – Chromosome 10 – (5-Hydroxytryptamine Receptor 7) is a Protein Coding gene. Diseases associated with HTR7 include Autistic Disorder and Byssinosis.

ETS1 – Chromosome 11 – (ETS Proto-Oncogene 1, Transcription Factor) is a Protein Coding gene. Among its related pathways are Photodynamic therapy-induced NF-kB survival signaling and MAPK-Erk Pathway. GO annotations related to this gene include transcription factor activity, sequence-specific DNA binding and transcription factor binding. An important paralog of this gene is ETS2.

HTR2A – Chromosome 13 – (5-Hydroxytryptamine Receptor 2A) is a Protein Coding gene. Diseases associated with HTR2A include Schizophrenia and Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment.

SLC6A4 – Chromosome 17 – (Solute Carrier Family 6 Member 4) is a Protein Coding gene. Diseases associated with SLC6A4 include Obsessive-Compulsive Disorder and Slc6a4-Related Altered Drug Metabolism.

TCF4 – Chromosome 18 – (Transcription Factor 4) is a Protein Coding gene. Among its related pathways are Mesodermal Commitment Pathway and Regulation of Wnt-mediated beta catenin signaling and target gene transcription. GO annotations related to this gene include transcription factor activity, sequence-specific DNA binding and protein heterodimerization activity. An important paralog of this gene is TCF12.

OXT – Chromosome 20 – (Oxytocin/Neurophysin I Prepropeptide) is a Protein Coding gene. This gene encodes a precursor protein that is processed to produce oxytocin and neurophysin I. Oxytocin is a posterior pituitary hormone which is synthesized as an inactive precursor in the hypothalamus along with its carrier protein neurophysin I. Together with neurophysin, it is packaged into neurosecretory vesicles and transported axonally to the nerve endings in the neurohypophysis, where it is either stored or secreted into the bloodstream. The precursor seems to be activated while it is being transported along the axon to the posterior pituitary. This hormone contracts smooth muscle during parturition and lactation. It is also involved in cognition, tolerance, adaptation, and complex sexual and maternal behavior, as well as in the regulation of water excretion and cardiovascular functions.

AVP – Chromosome 20 – (Arginine Vasopressin) is a Protein Coding gene. Diseases associated with AVP include Diabetes Insipidus, Neurohypophyseal and Hereditary Central Diabetes Insipidus. Among its related pathways are G alpha (s) signalling events and HIV Life Cycle. GO annotations related to this gene include protein kinase activity and signal transducer activity. An important paralog of this gene is OXT.

These genes represent only a fraction of the neurochemistry control sites, but they are disproportionately represented in terms of impact due to being frequently targeted by a wide variety of damaging sources focused on addiction, conditioning, reward-behaviors, and various forms of trauma.  By changing the dimensions of a region that methylation, phosphorylation, acetylation, and histone modification have to cover the recalculation is triggered and optimized to the current environment. [15] Tuesta, L. M., & Zhang, Y. (2014), [16] Samonte FGR.(2017)

It is also worth noting that in the case of more extreme imbalances two or more gene targets would either need to be iteratively, or simultaneously, recalculated in order to reach a balanced state. By using one gene therapy, then a second on the parallel site, such as the case with OXT vs. AVP balance, you could iteratively progress towards a balanced state with less extreme gene expression levels, like turning the sides of a Rubik’s Cube. Using multiple versions of the same gene therapy, attaching to different target sites, this process could be activated simultaneously, causing the recalculation to factor in all discovered and targeted regions at once, effectively “training” the epigenetic weights of highly connected regions, instead of working iteratively where half of them are frozen at any given time. Initially this simultaneous trigger could be via standard injection, but it could also be automated a variety of ways, including using links to circadian rhythm conditions and seasonal changes, causing routine recalculation of mental and emotional health critical gene expression. [17] Neumann, ID, Landgraf R.(2012)

Since none of the genes are directly impacted, only recalculating their level of activation, risk is kept to a bare minimum, and the same approach can be repeated to yield different results by varying the conditions present as the gene therapy takes effect.  Ideal circumstances for any given outcome can be established by varying environmental factors until the result is optimized, potentially even personalized, and though this approach would be ideally suited for a laboratory environment, it could also help to establish best-practices for administering the gene therapies once they reached human trials.

Results of epigenetic recalculation could be further utilized for mathematically modeling the potential space of gene activation when coupled with environmental data from the trial facility, increasing prediction accuracy for post-therapy gene expression, as well as the subsequent benefits.

The before-versus-after comparison between fully mapped genomes could also be used in Deep Neural Network terms to generate accurate predictions for post-therapy gene activation levels and the approximate benefits of those changes. A DNN could even be modeled to map causal relationships between epigenetic activation changes in a way that has likely never been done before, allowing for many genes with currently unknown functions to be defined, opening the door to more advanced models that could map the causal and probable space of genetic engineering with far greater accuracy.

In Closing:

How long we remain mired in the Medieval times of genetic engineering is purely up to us, as a collective we can form a safety committee which agrees to create a practical gene therapy that shifts the paradigm away from monopolistic control to one where science can advance, and people can benefit from advances without waiting 20 years for approval.

The best way to win the hearts and minds of people around the world is to give them something to be grateful for, benefiting either themselves or those they love in meaningful ways. I can think of no better start down this path than curing the epigenetic effects of trauma, as virtually everyone has suffered some form of trauma in their lives, and many are needlessly crippled by it today.

Without the scars left on humanity at the epigenetic level the negative-influence house of cards collapses, along with all of the industries who prey upon it, breaking the downward spiral and moving the dial forward, from pointing towards a deeper Dystopia to a brighter future.

Transhumanism is likewise about the freedom to choose who you are, and who you become, which in the field of genetic engineering means that a practical method for genetic updates is as much a prerequisite as the computer was a prerequisite for the Internet. It would by no means remove the threat of archaic legal constructs, but it would greatly reduce their potency, taking us one step closer to being truly Transhuman.

Taking this a step further, the ability to reset the epigenetic level influence of trauma, addiction, and conditioned behaviors is also prerequisite to any major social change, as backlash comes into play when friction of the old meets new paradigms. The act of curing the effects of trauma would in this way also serve to make people more open to new ideas, since the baseline of their neurochemistry shifting would trigger subsequent recalculation going up the chain, all the way to higher order cognitive functions. This could potentially be used to shift neurochemistry into unexplored probability space, allowing for configurations that couldn’t arise naturally.

Without the practical potential there is no room for innovation, and progress stagnates behind monumental pay-gates, but the solution can be engineered today, giving innovators access to build a better tomorrow.

Humanity is but one life form among billions of ever-evolving forms of life that we know of today, and even if only 1 in 10,000 of those lifeforms were evolving in ways compatible with our genetic structure we’d be wasting 99.9999% of the potential evolutionary improvements being made by other species.  Life in the known universe is in a perpetual race to evolve, and to compete in that race in any meaningful way, increasing the survival of the species, it is necessary to take advantage of the advances that other forms of life make, the other 99.9999%+ compute power dedicated to the task of evolving into ever more advanced and resilient beings.  While humanity may not be ready to take this step any time soon, perhaps once the world is cured of trauma this will enter the realm of consideration.

If humanity is to survive, let alone thrive, in the hazards of space, genetic engineering that grants us the resilience of life forms able to survive considerable exposure to radiation, extreme temperatures, increased gravity, and even the vacuum of space, are required for us to move forward. Even survival on Earth is a moving target, and as humanity stands today, vulnerability to any number of cataclysms remains much higher than it could be. Fans of longevity research should favor the generation of a practical gene therapy most of all, because it would only take a few direct gene edits using such a therapy to significantly increase life span, granting talented scientists more years with which they could work towards overcoming challenge after challenge.

Limiting gene therapy treatment to the rarest of diseases is like limiting internet access to the most remote parts of the world, an astronomical waste, and it is time for that to change. From the more directly Transhumanist perspective, this is a step towards being free to choose who you are right down to the genetic level, accessible to everyone, a basic human right that has yet to be written, but before reaching that point humanity needs an epigenetic tabula rasa, a slate clean of trauma, conditioning, and addiction.

Kyrtin Atreides is a researcher and member of the U.S. Transhumanist Party. In his spare time over the past two years, he has conducted research into Psychoacoustics, Quantum Physics, Genetics, Language (Advancement of), Deep Learning / Artificial General Intelligence (AGI), and a variety of other branching domains, and continues to push the limits of what can be created or discovered.

For additional reading on the subject matter mentioned herein, please refer to:

Lentivirus: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837622/

https://viralzone.expasy.org/264?outline=all_by_species

Adeno-Associated Virus: https://www.wjgnet.com/2220-3184/full/v5/i3/28.htm

https://microbewiki.kenyon.edu/index.php/Epstein-Barr_Virus

Formal Citations:

1. De Bellis, M. D., & A.B., A. Z. (2014). “The Biological Effects of Childhood Trauma.” Child and Adolescent Psychiatric Clinics of North America23(2), 185–222. http://doi.org/10.1016/j.chc.2014.01.002

2. Gudsnuk, K., & Champagne, F. A. (2012). Epigenetic Influence of Stress and the Social Environment. ILAR Journal53(3-4), 279–288. http://doi.org/10.1093/ilar.53.3-4.279

3. Hardy, T. M., & Tollefsbol, T. O. (2011). Epigenetic diet: impact on the epigenome and cancer. Epigenomics3(4), 503–518. http://doi.org/10.2217/epi.11.71

4. Bowers, E. C., & McCullough, S. D. (2017). Linking the Epigenome with Exposure Effects and Susceptibility: The Epigenetic Seed and Soil Model. Toxicological Sciences155(2), 302–314. http://doi.org/10.1093/toxsci/kfw215

5. Teschendorff, A. E., West, J., & Beck, S. (2013). Age-associated epigenetic drift: implications, and a case of epigenetic thrift? Human Molecular Genetics22(R1), R7–R15. http://doi.org/10.1093/hmg/ddt375

6. Pakorn Aiewsakun, Aris Katzourakis(2015) Endogenous viruses: Connecting recent and ancient viral evolution. Virology. 2015 May;479-480:26-37. doi: 10.1016/j.virol.2015.02.011. Epub 2015 Mar 12.

7. Payne, R., Muenchhoff, M., Mann, J., Roberts, H. E., Matthews, P., Adland, E., … Goulder, P. J. R. (2014). Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence. Proceedings of the National Academy of Sciences of the United States of America111(50), E5393–E5400. http://doi.org/10.1073/pnas.1413339111

8. Eloe-Fadrosh, E. A., & Rasko, D. A. (2013). The Human Microbiome: From Symbiosis to Pathogenesis. Annual Review of Medicine64, 145–163. http://doi.org/10.1146/annurev-med-010312-133513

9. Houldcroft, C. J., & Kellam, P. (2015). Host genetics of Epstein–Barr virus infection, latency and disease. Reviews in Medical Virology25(2), 71–84. http://doi.org/10.1002/rmv.1816

10. Haifeng Chen. (2015) Adeno-associated virus vectors for human gene therapy. Published by Baishideng Publishing Group Inc. doi: 10.5496/wjmg.v5.i3.28

11. Welle, S., Cardillo, A., Zanche, M., & Tawil, R. (2009). Skeletal muscle gene expression after myostatin knockout in mature mice Address for reprint requests and other correspondence: S. Welle, Univ. of Rochester Medical Center, 601 Elmwood Ave., Box 693, Rochester, NY 14642 (e-mail: stephen_welle@urmc.rochester.edu). Physiological Genomics38(3), 342–350. http://doi.org/10.1152/physiolgenomics.00054.2009

12. White, M., Whittaker, R., Gándara, C., & Stoll, E. A. (2017). A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies. Human Gene Therapy Methods28(4), 163–176. http://doi.org/10.1089/hgtb.2017.096

13. Lillycrop KA1, Costello PM2, Teh AL3, Murray RJ2, Clarke-Harris R2, Barton SJ4, Garratt ES2, Ngo S5, Sheppard AM5, Wong J3, Dogra S3, Burdge GC2, Cooper C6, Inskip HM4, Gale CR7, Gluckman PD8, Harvey NC4, Chong YS9, Yap F10, Meaney MJ11, Rifkin-Graboi A3, Holbrook JD3; Epigen Global Research Consortium, Godfrey KM12. Int J Epidemiol. 2015 Aug;44(4):1263-76. doi: 10.1093/ije/dyv052.

14. Sandman CA, Curran MM, Davis EP, Glynn LM, Head K, Baram TZ.(2018) Am J Psychiatry. 2018 Mar 2:appiajp201716121433. doi: 10.1176/appi.ajp.2017.16121433.

15. Tuesta, L. M., & Zhang, Y. (2014). Mechanisms of epigenetic memory and addiction. The EMBO Journal33(10), 1091–1103. http://doi.org/10.1002/embj.201488106

16. Samonte FGR.(2017) The Epigenetic of Dopamine Reward in Obesity and Drug Addiction: A Philippine Perspective. J Clin Epigenet. 2017, 3:2. doi: 10.21767/2472-1158.100051

17. Neumann, ID, Landgraf R.(2012) Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci. 2012 Nov;35(11):649-59. doi: 10.1016/j.tins.2012.08.004. Epub 2012 Sep 11.

U.S. Transhumanist Party to Participate in RAAD Fest 2018

U.S. Transhumanist Party to Participate in RAAD Fest 2018

logo_bg

Gennady Stolyarov II


The U.S. Transhumanist Party will again be represented at RAAD Fest in San Diego. Chairman Gennady Stolyarov II will be attending RAAD Fest 2018 and will be moderating a panel of speakers as well as presenting regarding the accomplishments of the Transhumanist Party over the most recent year as of September 20-23, 2018. There will be an opportunity for a sizable Transhumanist Party presence, and we are contemplating a meeting of U.S. Transhumanist Party members that would be open to the public and media.

It is possible to register for RAAD Fest 2018 at the website raadfest.com. By entering the code TRANSHUMAN, attendees will be able to save $50 off of the cost of registration.

More details regarding Mr. Stolyarov’s presence and activities at RAAD Fest 2018 will be announced as they become available. We look forward to seeing you there!

Announcement of California Transhumanist Party 2nd Leadership Meeting on Sunday, April 22, 2018

Announcement of California Transhumanist Party 2nd Leadership Meeting on Sunday, April 22, 2018

Newton Lee


I am pleased to announce our 2nd Leadership Meeting on Earth Day, Sunday, April 22nd, 2018, at Woodbury University with a special treat: combining a peace conference movie screening and a Transhumanist Party meeting.

Sunday, April 22, 2018

Woodbury University

7500 N Glenoaks Blvd, Burbank, CA 91504

2 p.m. – 4 p.m.  Movie screening “Winds of Freedom” with Q&A at Fletcher Jones Auditorium (in the School of Business)

4 p.m. – 5 p.m.  California Transhumanist Party leadership meeting at Isaacs Faculty Center (same building as our last meeting)

Please mark your calendar, and order your free tickets online:

https://www.eventbrite.com/e/2018-earth-day-peace-conference-movie-screening-tickets-44054010732

Thank you, and see you on Earth Day 2018!

Newton Lee

Education and Media Advisor, United States Transhumanist Party (USTP)

Chairman, California Transhumanist Party (CTP)

http://www.CaliforniaTranshumanistParty.org

LinkedIn: https://www.linkedin.com/in/newtonlee/